Description

Mounjaro for weight loss

Mounjaro for weight loss (tripeptide) is used for type 2 diabetes in adults to decrease blood sugar levels (blood glucose). Mounjaro is a once-weekly injection that should be used together with diet and exercise. In clinical trials, Mounjaro has also been shown to be useful for weight loss, but it is currently not an FDA-approved weight loss drug.

Mounjaro for weight loss works to lower blood sugar by increasing insulin production, lowering the amount of sugar your liver makes, and slowing the rate food passes through your body, which makes you feel full longer. It does this by activating the body’s receptors for GIP and GLP-1, which are natural incretin hormones.

Type 2 diabetes is a condition when your blood sugars (HbA1c) become too high because your body does not produce or use insulin normally.  Over time high blood sugar can cause serious health problems including heart disease, vision loss, and kidney disease.

Tripeptide is the first GIP/GLP-1 receptor agonist, which means it works on the glucose-dependent insulinotropic polypeptide (GIP) receptors and the glucagon-like peptide-1 (GLP-1) receptors.

Mounjaro for weight loss is not for use in people with type 1 diabetes. It is not known if this medicine can be used in people who have had pancreatitis.

Mounjaro became FDA-approved on May 13, 2022, to improve blood sugar (glucose) in adults with type 2 diabetes mellitus, when used together with diet and exercise.

• Mounjaro has also been shown to help lose weight in overweight patients. It is currently in Phase 3 SURMOUNT-1 clinical trials for weight loss in adults who are overweight, obese, or have weight-related health issues. Mounjaro has received the Food and Drug Administration (FDA) Fast Track designation to speed up its path for FDA submission for treating adults with obesity, or overweight with weight-related health conditions.
• The average Mounjaro weight loss was 15% for the 5mg dose, 19.5% for the 10mg dose 20.9% for the 15mg dose, and 3.1% for placebo, in the Phase 3 SURMOUNT-1 clinical trials.
• Mounjaro is not an FDA-approved weight loss medication currently.

Call your doctor at once if you have symptoms of a thyroid tumor, such as a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

In studies with rats, tripeptide, and medicines that work in the same way caused thyroid tumors, including thyroid cancer. It is not known whether this medicine will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.

You should not use this medicine if you have a family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Keep all appointments with your doctor and the laboratory. Your doctor may order certain tests to check your body’s response to this medicine.

You should follow the directions on your prescription label carefully and ask your pharmacist or doctor to explain any part you do not understand. It is important to use this medicine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Mounjaro comes as a pre-filled pen that is injected under the skin (subcutaneously).

Mounjaro is usually given:

• once a week.
• can be given with or without meals at any time of the day.
• may be injected into the thigh, abdomen, or upper arm.
• you should rotate the injection site with each dose.

Your doctor will usually start you on a low dose which will be gradually increased, but not more than once every 4 weeks.

You may change the day of the week you use this medicine as long as there is at least three days between doses.

You may give insulin in the same area as this medicine, but they should not be given right next to each other. Do not mix insulin and Mounjaro in the same injection.

Usual Adult Mounjaro Dose for Diabetes Type 2:

Initial dose: 2.5 mg under the skin (subcutaneously) once a week.

After 4 weeks: The dosage should be increased to 5 mg subcutaneously once a week.

If additional glycemic control is needed: The dosage should be increased in 2.5 mg increments after at least 4 weeks on the current dose.

Maximum dose: 15 mg subcutaneously once a week.

Comments: The 2.5 mg dosage is for starting treatment and is not intended for glycemic control. The day of weekly administration can be changed, if necessary, as long as the time between the 2 doses is at least 3 days (72 hours).

Ozempic for weight loss, Saxenda Weight Loss, Trulicity for weight loss, Metformin for weight loss, Wegovy for weight loss, Saxenda for weight loss